Patent 9474780 was granted and assigned to Eli Lilly and Company on October, 2016 by the United States Patent and Trademark Office.
The present invention relates to dual incretin peptide mimetic compounds that agonize receptors for both human glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), and may be useful for treating type 2 diabetes mellitus (T2D).